Like many biopharma companies, Evofem has found difficulty in successfully growing the market share for its core products. Among the core products investors have looked to for growth is the company’s Phexxi vaginal gel. This gel works as a contraceptive and is an alternative to more traditional birth control options. In addition to Phexxi, the company has a number of other interesting products under development. These include EVO100, an antimicrobial vaginal gel aimed at preventing the transmission of various sexually transmitted infections.$Evofem Biosciences Inc.(EVFM)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments